Skip to content
Inciteful Med

Standard of Care Treatment: Your Options

Last updated:

Myasthenia gravis treatment aims to achieve minimal symptoms through a personalized approach. Options include rapid-acting symptom relief like Mestinon, long-term immunosuppressants, targeted biologics, and thymectomy. Patients with MuSK-positive MG often respond best to Rituximab.

Key Takeaways

  • • The ultimate goal of myasthenia gravis treatment is minimal manifestation status, meaning you experience few to no symptoms that interfere with daily life.
  • • Pyridostigmine provides rapid, temporary symptom relief but does not address the underlying immune system attack causing the disease.
  • • A thymectomy is often recommended for generalized MG patients with AChR antibodies to improve long-term muscle strength and lower steroid use.
  • • New targeted biologics, such as FcRn antagonists and complement inhibitors, offer options for patients who do not respond to standard immunosuppressants.
  • • Patients with MuSK-positive MG often require different treatments, with Rituximab widely considered a highly effective first-line option.

Treating Myasthenia Gravis (MG) is a highly personalized process. Because every person’s immune system is unique, your doctor will likely use a combination of therapies to reach the goal of “minimal manifestation status”—a state where you have little to no symptoms that interfere with your daily life [1][2].

The Treatment Hierarchy

Doctors typically approach MG treatment in five stages, moving from immediate symptom relief to long-term immune management:

  1. Symptomatic Relief: Pyridostigmine (Mestinon) is the most common first-line treatment [3]. It is an acetylcholinesterase inhibitor, which works by stopping the breakdown of the chemical signal (acetylcholine) that tells your muscles to move [4][5]. It works quickly—often within hours—but it is like a “band-aid”; it helps the muscles work better but does not stop the underlying immune attack [5][4].
  2. Calming the Immune System: To address the root cause, doctors use immunosuppressants.
    • Prednisone: A corticosteroid that works relatively quickly (weeks to months) but can have significant long-term side effects [6][7].
    • Steroid-Sparing Agents: Medications like Azathioprine (AZA) or Mycophenolate Mofetil (MMF) are used to allow you to take less prednisone [6][8]. These take a long time to work—often 10 to 17 months to reach their full effect [8].
    • ⚠️ Safety Warning: Mycophenolate Mofetil (MMF) carries severe black-box warnings for causing birth defects (teratogenicity). It requires strict contraception and must not be used during pregnancy [6][9].
  3. Surgical Intervention: A thymectomy (surgical removal of the thymus gland) is often recommended for patients with the AChR antibody [2][10]. A major study called the MGTX trial proved that for generalized MG patients, having a thymectomy can lead to better muscle strength and a lower need for daily steroids over a five-year period, even if no tumor is present [2][11].
  4. Targeted Biologics (The New Era): For patients who don’t respond to standard drugs, new targeted therapies are now available:
    • FcRn Antagonists: Drugs like Efgartigimod (Vyvgart) work by lowering the level of harmful antibodies in your blood by preventing them from being recycled back into your system [12][13].
    • Complement Inhibitors: Drugs like Eculizumab (Soliris) or Ravulizumab (Ultomiris) block a specific part of the immune system (the complement system) that causes physical damage to the muscle’s “docking stations” [14][15].
    • ⚠️ Safety Warning: Because complement inhibitors block a key part of your immune system, they carry a black-box warning for life-threatening meningococcal infections. They strictly require specialized vaccinations before you can begin treatment [14][15].
  5. Rescue Therapies: In emergencies or severe flare-ups, doctors use Intravenous Immunoglobulin (IVIG) or Plasma Exchange (PLEX) to rapidly remove or neutralize harmful antibodies [16][17]. PLEX can sometimes provide relief faster (within two weeks) than IVIG [17].

A Special Note on MuSK-MG

If you have MuSK-positive MG, your treatment path is different [18]. Many MuSK patients find that Pyridostigmine (Mestinon) is ineffective or even causes unpleasant side effects like muscle twitching and cramping [19][20]. For this subtype, a targeted therapy called Rituximab is often considered a highly effective, first-line option that can lead to long-term remission [21][22].

Timing and Expectations

It is important to manage expectations regarding how long these treatments take to work:

  • Hours: Pyridostigmine (Mestinon) [5].
  • Weeks to Months: Prednisone, IVIG, PLEX, and newer biologics like Efgartigimod [6][17][23].
  • Months to Years: Azathioprine, Mycophenolate, and the full benefits of a thymectomy [8][2].

Finding the right “cocktail” of treatments takes time, patience, and close communication with an expert. Read about Building Your Care Team for advice on managing this process.

Frequently Asked Questions

How long does it take for myasthenia gravis medications to work?
The timeframe depends entirely on the specific treatment. Symptom relief medications like Mestinon can work within hours, while steroids and newer biologics generally take weeks to months. Steroid-sparing immunosuppressants and thymectomy surgery may take months to years to show their full benefits.
What is the best treatment for MuSK-positive myasthenia gravis?
Patients with MuSK-positive myasthenia gravis often require a different treatment approach. Standard medications like Mestinon may be ineffective or cause severe muscle cramping, so doctors frequently recommend targeted therapies like Rituximab as a highly effective first-line option.
What is rescue therapy for myasthenia gravis?
Rescue therapies are utilized during emergencies or severe symptom flare-ups, particularly if you have trouble swallowing. Doctors use treatments like Intravenous Immunoglobulin (IVIG) or Plasma Exchange (PLEX) to rapidly neutralize or remove harmful antibodies from your bloodstream.
Do I need a thymectomy if I have myasthenia gravis?
A thymectomy, or surgical removal of the thymus gland, is often recommended for generalized myasthenia gravis patients who have the AChR antibody. Clinical trials demonstrate that this surgery can lead to better long-term muscle strength and a reduced need for daily steroids, even if no tumor is present.

Questions for Your Doctor

  • • Based on my antibody type and symptom severity, which medication should we start with first?
  • • If we start a 'steroid-sparing' drug like Azathioprine or Mycophenolate, how will we manage my symptoms during the months it takes to become fully effective?
  • • Am I a candidate for a thymectomy, and what does the MGTX trial suggest about the long-term benefits for someone in my situation?
  • • If I don't respond well to first-line treatments, at what point should we consider the newer targeted biologics?
  • • What is our plan for 'rescue therapy' if my symptoms suddenly become severe or I have trouble swallowing?

Questions for You

  • • How quickly did you notice a difference after taking your first dose of Pyridostigmine (Mestinon)?
  • • Are you able to tolerate the side effects of your current medications, or are they significantly impacting your quality of life?
  • • Do you feel that your current treatment is allowing you to reach 'minimal manifestation status'—meaning you have few to no symptoms that interfere with your day?
  • • If you have MuSK-positive MG, have you noticed any unusual twitching or cramping when taking Mestinon?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report.

    Ohara H, Kikutsuji N, Iguchi N, Kinoshita M

    BMC neurology 2024; (24(1)):292 doi:10.1186/s12883-024-03804-y.

    PMID: 39174898
  2. 2

    Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

    Wolfe GI, Kaminski HJ, Aban IB, et al.

    The Lancet. Neurology 2019; (18(3)):259-268 doi:10.1016/S1474-4422(18)30392-2.

    PMID: 30692052
  3. 3

    Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.

    Lorenzoni PJ, Kay CSK, Ducci RD, et al.

    Arquivos de neuro-psiquiatria 2020; (78(3)):179-181 doi:10.1590/0004-282x20190189.

    PMID: 32215460
  4. 4

    How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?

    Gwathmey KG, Ding H, Hehir M, Silvestri N

    Muscle & nerve 2024; (69(4)):389-396 doi:10.1002/mus.28038.

    PMID: 38308492
  5. 5

    Pediatric Ocular Myasthenia Gravis.

    Fisher K, Shah V

    Current treatment options in neurology 2019; (21(10)):46 doi:10.1007/s11940-019-0593-y.

    PMID: 31559492
  6. 6

    Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.

    Johnson S, Katyal N, Narula N, Govindarajan R

    Medical science monitor : international medical journal of experimental and clinical research 2021; (27()):e933296 doi:10.12659/MSM.933296.

    PMID: 34707081
  7. 7

    Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

    Benatar M, Mcdermott MP, Sanders DB, et al.

    Muscle & nerve 2016; (53(3)):363-9 doi:10.1002/mus.24769.

    PMID: 26179124
  8. 8

    The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

    Sanders DB, Lutz MW, Raja SM, et al.

    Muscle & nerve 2026; doi:10.1002/mus.70177.

    PMID: 41700316
  9. 9

    Outcomes of myasthenia gravis patients admitted to the Intensive Care Unit: Experience from a tertiary care center in Saudi Arabia.

    Attar A, Alshaikh H, Alharbi G, et al.

    PloS one 2025; (20(7)):e0328648 doi:10.1371/journal.pone.0328648.

    PMID: 40720448
  10. 10

    Minimal manifestation status and prednisone withdrawal in the MGTX trial.

    Lee I, Kuo HC, Aban IB, et al.

    Neurology 2020; (95(6)):e755-e766 doi:10.1212/WNL.0000000000010031.

    PMID: 32611638
  11. 11

    [The Significance of Extended Thymectomy in Non-Thymomatous Myasthenia Gravis: an MGTX Study].

    Yoshikawa H

    Brain and nerve = Shinkei kenkyu no shinpo 2017; (69(1)):51-59 doi:10.11477/mf.1416200636.

    PMID: 28126978
  12. 12

    Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.

    Bril V, Howard JF, Karam C, et al.

    European journal of neurology 2024; (31(1)):e16098 doi:10.1111/ene.16098.

    PMID: 37843174
  13. 13

    Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications.

    Mansour GK, Alangari L, Khosyfan L, et al.

    Biomedicines 2025; (13(12)) doi:10.3390/biomedicines13122975.

    PMID: 41462987
  14. 14

    Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.

    Vu T, Wiendl H, Katsuno M, et al.

    Neuropsychiatric disease and treatment 2023; (19()):2639-2655 doi:10.2147/NDT.S374694.

    PMID: 38059203
  15. 15

    Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.

    Vu T, Meisel A, Mantegazza R, et al.

    NEJM evidence 2022; (1(5)):EVIDoa2100066 doi:10.1056/EVIDoa2100066.

    PMID: 38319212
  16. 16

    Clinical and economic outcomes of myasthenia gravis and myasthenic crisis when treated with PLEX and IVIG.

    Maroney M, Diehl T, Blaney E, et al.

    Frontiers in neurology 2025; (16()):1713388 doi:10.3389/fneur.2025.1713388.

    PMID: 41356249
  17. 17

    Plasma Exchange versus Intravenous Immunoglobulin in Worsening Myasthenia Gravis: A Systematic Review and Meta-Analysis with Special Attention to Faster Relapse Control.

    Pavlekovics M, Engh MA, Lugosi K, et al.

    Biomedicines 2023; (11(12)) doi:10.3390/biomedicines11123180.

    PMID: 38137401
  18. 18

    Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.

    Clifford KM, Hobson-Webb LD, Benatar M, et al.

    Muscle & nerve 2019; (59(4)):404-410 doi:10.1002/mus.26404.

    PMID: 30575980
  19. 19

    Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: A neurophysiological study.

    Modoni A, Mastrorosa A, Spagni G, Evoli A

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2021; (132(8)):1845-1849 doi:10.1016/j.clinph.2021.04.019.

    PMID: 34147009
  20. 20

    A clinical perspective on muscle specific kinase antibody positive myasthenia gravis.

    Keritam O, Vincent A, Zimprich F, Cetin H

    Frontiers in immunology 2024; (15()):1502480 doi:10.3389/fimmu.2024.1502480.

    PMID: 39703505
  21. 21

    Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.

    Sachdeva J, Mahesh KV, Shree R, et al.

    Indian journal of pharmacology 2020; (52(1)):49-52 doi:10.4103/ijp.IJP_333_18.

    PMID: 32201447
  22. 22

    Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.

    Dalakas MC

    Current opinion in neurology 2020; (33(5)):545-552 doi:10.1097/WCO.0000000000000858.

    PMID: 32833750
  23. 23

    Myasthenia gravis: The evolving therapeutic landscape.

    Wolfe GI, Hanson JE, Silvestri NJ

    eNeurologicalSci 2024; (37()):100541 doi:10.1016/j.ensci.2024.100541.

    PMID: 39649986

This page provides educational information about standard treatments for myasthenia gravis. Always consult your neurologist to determine the safest and most effective medication plan for your specific antibody type and symptoms.

Stay up to date

Get notified when new research about Myasthenia gravis is published.

No spam. Unsubscribe anytime.